Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Iressa failure raises fears about accelerated approvals

Nature Reviews Drug Discovery volume 4, page 94 (2005)Cite this article

Concerns that the regulatory bar might be raised for oncology drugs.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Simon Frantz
    View author publications

    Search author on:PubMed Google Scholar

Related links

Related links

Related external links

FDA statement on Iressa

National Cancer Institute summary on Iressa

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frantz, S. Iressa failure raises fears about accelerated approvals. Nat Rev Drug Discov 4, 94 (2005). https://doi.org/10.1038/nrd1649

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nrd1649

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing